EUVIMEDEUVIMED entdecken
Kohortenstudie

Clinical utility of non-induced sputum galactomannan testing for suspected invasive pulmonary aspergillosis: a real-world retrospective cohort study

Chia-Ta Tsai, Shin-Yi Liang, Chung-Hsu Lai, Ying-Nan Tsai, Chien-Tung Chiu, Chun-Kai Huang

Infection · 2026-06 · 54 (3) · 1479-1486

DOI: 10.1007/s15010-026-02784-0 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Infection, online erschienen am 28.03.2026. Verfasst von Chia-Ta Tsai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. protass0203@gmail.com. Hauptthemen laut MEDLINE: Mannans, Sputum, Invasive Pulmonary Aspergillosis. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Non-induced sputum galactomannan (GM) testing is increasingly used in routine evaluation of suspected invasive pulmonary aspergillosis (IPA), yet its real-world performance and the clinical implications of negative results remain incompletely characterised. We aimed to evaluate its diagnostic performance relative to bronchoscopic mycological findings and to describe the short-term evolution of GM results in routine practice. METHODS: We retrospectively analysed adult patients who underwent non-induced sputum GM testing between 2017 and 2025. Diagnostic performance was assessed in patients with paired sputum and bronchoscopic samples obtained within 7 days using a bronchoscopy-based composite mycological reference standard (defined as bronchoscopic GM index ≥ 0.5, positive Aspergillus culture, or histopathological evidence of invasion). Longitudinal GM evolution was described in patients with initially negative sputum GM results. RESULTS: Among 1002 patients, 73 had paired samples. Sputum GM demonstrated a sensitivity of 73.7% (95% CI 53.9-93.5%), specificity of 72.2% (95% CI 60.3-84.2%), positive predictive value of 48.3% (95% CI 30.1-66.5%), and negative predictive value of 88.6% (95% CI 79.3-98.0%) for composite bronchoscopic mycological positivity. Higher sputum GM indices were associated with increasing rates of composite bronchoscopic mycological positivity (P for trend = 0.003). Among patients with initially negative sputum GM who underwent repeat testing, early follow-up (days 8-30) showed GM signal evolution in 15.1% of retested patients, whereas subsequent serum or bronchoscopic GM positivity remained uncommon (3.8%); both proportions increased with longer observation. CONCLUSION: In routine clinical practice, non-induced sputum GM testing demonstrates moderate diagnostic performance relative to bronchoscopic mycological findings. Negative results were associated with low short-term rates of subsequent bronchoscopic or serum GM positivity. These findings may inform short-term clinical reassessment, particularly in settings where bronchoscopy is not readily available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MannansSputumInvasive Pulmonary AspergillosisHumansGalactoseRetrospective StudiesFemaleMaleMiddle AgedSensitivity and SpecificityAgedAdultBronchoscopyPredictive Value of Tests

Stichwörter der Autor:innen

Diagnostic accuracyGalactomannanInvasive pulmonary aspergillosisLongitudinal follow-upNegative predictive valueSputum

Substanzen

MannansgalactomannanGalactose

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. protass0203@gmail.com.
  • Department of Infection Control, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. protass0203@gmail.com.
  • Department of Pharmacy, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Division of Infectious Diseases, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Department of Critical Care Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.

Zitieren

APA

Tsai, C. T., Liang, S. Y., Lai, C. H., Tsai, Y. N., Chiu, C. T., & Huang, C. K. (2026). Clinical utility of non-induced sputum galactomannan testing for suspected invasive pulmonary aspergillosis: a real-world retrospective cohort study. Infection, 54(3), 1479-1486. https://doi.org/10.1007/s15010-026-02784-0

Vancouver

Tsai CT, Liang SY, Lai CH, Tsai YN, Chiu CT, Huang CK. Clinical utility of non-induced sputum galactomannan testing for suspected invasive pulmonary aspergillosis: a real-world retrospective cohort study. Infection. 2026;54(3):1479-1486. doi:10.1007/s15010-026-02784-0

BibTeX
@article{Tsai2026,
  author = {Tsai, Chia-Ta and Liang, Shin-Yi and Lai, Chung-Hsu and Tsai, Ying-Nan and Chiu, Chien-Tung and Huang, Chun-Kai},
  title = {Clinical utility of non-induced sputum galactomannan testing for suspected invasive pulmonary aspergillosis: a real-world retrospective cohort study},
  journal = {Infection},
  year = {2026},
  volume = {54},
  number = {3},
  pages = {1479--1486},
  doi = {10.1007/s15010-026-02784-0}
}
Kostenlos starten →